ВАКЦИНАЦИЯ ПРОТИВ РОТАВИРУСНОЙ ИНФЕКЦИИ: 10-ЛЕТНИЙ МИРОВОЙ ОПЫТ УСПЕШНОГО ПРИМЕНЕНИЯ

Статья содержит  обзор результатов научных исследований, опубликованных за последние несколько лет, подтверждающих значительное  социально-экономическое бремя ротавирусной инфекции и ее весомый вклад  в заболеваемость и смертность детского  населения  планеты.  Авторами представлены  доказательства эффективности  использования иммунизации в условиях рутинного графика профилактических прививок младенцев  как в развитых, так и развивающихся странах. Показано  значимое снижение  уровня смертности и госпитализаций  вследствие  тяжелых форм  ротавирусного  гастроэнтерита  в течение первых лет  внедрения  ротавирусной  вакцинации,  что обозначило положительный тренд развития здравоохранения.

1. who.int [Internet]. Distribution of the estimated deaths among children under 5 years of age, from diseases that are preventable by vaccination in 2008 [cited 2017 Jul 1]. Available from: http://www.who.int/immunization/monitoring_surveillance/burden/estimates/en/.

2. Tate JE, Burton AH, Boschi-Pinto C, et al. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000-2013. Clin Infect Dis. 2016;62 Suppl 2:S96–S105. doi: 10.1093/cid/civ1013.

3. Tate JE, Burton AH, Boschi-Pinto C, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(2):136–141. doi: 10.1016/S1473-3099(11)70253-5.

4. WHO Global rotavirus surveillance network — a strategic review of the first 5 years (2008–2012). Wkly Epidemiol Rec. 2014;89(30):340–344.

5. Bernstein DI. Rotavirus overview. Pediatr Infect Dis J. 2009;28(3 Suppl):S50-53. doi: 10.1097/INF.0b013e3181967bee.

6. Государственный доклад «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2016 году». — М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека; 2017. — 220 с. [Gosudarstvennyi doklad «O sostoyanii sanitarno-epidemiologicheskogo blagopoluchiya naseleniya v Rossiiskoi Federatsii v 2016 godu». Moscow: Federal’naya sluzhba po nadzoru v sfere zashchity prav potrebitelei i blagopoluchiya cheloveka; 2017. 220 p. (In Russ).]

7. Плоскирева А.А. Острые кишечные инфекции вирусной этиологии у детей: клиника, диагностика и терапия: Автореф. … докт. мед. наук. — М.; 2016. — 49 с. [Ploskireva AA. Ostrye kishechnye infektsii virusnoi etiologii u detei: klinika, diagnostika i terapiya. [dissertation abstract] Moscow; 2016. 49 p. (In Russ).]

8. Лукьянова А.М., Бехтерева М.К., Птичникова Н.Н. Клиникоэпидемиологическая характеристика вирусных диарей у детей // Журнал инфектологии. — 2014. — Т.6. — №1 — С. 60–66. [Lukjanova AM, Bekhtereva MK, Ptichnikova NN. Clinical and epidemiological characteristic viral diarrhea in children. Jurnal infektologii. 2014;6(1):60–66. (In Russ).]

9. Lobzin YV, Kharit SM, Goveia MG, et al. Burden of childhood rotavirus disease in the outpatient setting of the Russian Federation.. Pediatr Infect Dis J. 2017;36(5):472–476. doi: 10.1097/INF.0000000000001472.

10. Vesikari T, Van Damme P, Giaquinto C, et al. European Society for Paediatric Infectious Diseases consensus recommendations for rotavirus vaccination in Europe: update 2014. Pediatr Infect Dis J. 2015;34(6):635–643. doi: 10.1097/Inf.0000000000000683.

11. Chandran A, Heinzen RR, Santosham M, Siberry GK. Nosocomial rotavirus infections: a systematic review. J Pediatr. 2006;149(4):441–447. doi: 10.1016/j.jpeds.2006.01.054.

12. Таточенко В.К. Вакцинопрофилактика ротавирусной инфекции // Медицинский совет. — 2016. — №7 — С. 36–38. [Tatochenko VK. Rotavirus vaccination. Medical Council. 2016;(7): 36–38. (In Russ).] doi: 10.21518/2079-701x-2016-07-36-38.

13. Феклисова Л.В., Шаповалова Р.Ф., Лиханская Е.И., и др. Экскреция ротавирусов в фекалиях пациентов педиатрических стационаров в течение года // Врач. — 2016. — №10 — С. 77–82. [Fekllsova LV, Shapovalova RF, Likhanskaya EI, et al. Fecal rotaviruses excretion in patients at children’s hospitals during a year. Vrach (Moscow, Russia). 2016;(10):7–82. (In Russ).]

14. Костинов М.П., Зверев В.В. Экономическая эффективность вакцинации против ротавирусной инфекции в Российской Федерации // Журнал микробиологии, эпидемиологии и иммунобиологии. — 2012. — №3 — С. 50–55. [Kostinov MP, Zverev VV. Ekonomicheskaya effektivnost’ vaktsinatsii protiv rotavirusnoi infektsii v Rossiiskoi Federatsii. Journal of microbiology, epidemiology, and immunobiology. 2012;(3):50–55. (In Russ).]

15. Rotavirus vaccines: an update. Wkly Epidemiol Rec. 2009;84(50):533–540.

16. Loharikar A, Dumolard L, Chu S, et al. Status of new vaccine introduction — worldwide, September 2016. MMWR Morb Mortal Wkly Rep. 2016;65(41):1136–1140. doi: 10.15585/mmwr.mm6541a3.

17. who.int [Internet]. WHO vaccine-preventable diseases: monitoring system. 2016 global summary [cited 2017 Jul 8]. Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules.

18. Santosham M, Steele D. Rotavirus vaccines a new hope. N Engl J Med. 2017;376(12):1170–1172. doi: 10.1056/NEJMe1701347.

19. Soares-Weiser K, MacLehose H, Bergman H, et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012;(2):CD008521 doi: 10.1002/14651858.CD008521.pub3.

20. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. doi: 10.1056/NEJMoa052434.

21. Zaman K, Dang DA, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebocontrolled trial. Lancet. 2010;376(9741):615–623. doi: 10.1016/S0140-6736(10)60755-6.

22. Breiman RF, Zaman K, Armah G, et al. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30 Suppl 1:A24–A29. doi: 10.1016/j.vaccine.2011.08.124.

23. Cunliffe NA, Witte D, Ngwira BM, et al. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: A randomized, double-blind, placebo controlled trial. Vaccine. 2012;30 Suppl 1:A36–A43. doi: 10.1016/j.vaccine.2011.09.120.

24. Aliabadi N, Tate JE, Haynes AK, Parashar UD. Sustained decrease in laboratory detection of rotavirus after implementation of routine vaccination — United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2015;64(13):337–342.

25. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. doi: 10.1056/NEJMoa052664.

26. Jonesteller CL, Burnett E, Yen C, et al. Effectiveness of Rotavirus Vaccination: а systematic review of the first decade of global postlicensure data, 2006-2016. Clin Infect Dis. 2017;65(5):840–850. doi: 10.1093/cid/cix369.

27. Burnett E, Jonesteller CL, Tate JE, et al. Global impact of rotavirus vaccination on childhood hospitalizations and mortality from diarrhea. J Infect Dis. 2017;215(11):1666–1672. doi: 10.1093/infdis/jix186.

28. Patel MM, Glass R, Desai R, et al. Fulfilling the promise of rotavirus vaccines: how far have we come since licensure? Lancet Infect Dis. 2012;12(7):561–570. doi: 10.1016/S1473-3099(12) 70029-4.

29. Paulke-Korinek M, Kundi M, Rendi-Wagner P, et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine. 2011;29(15):27912796. doi: 10.1016/j.vaccine.2011.01.104.

30. Buttery JP, Lambert SB, Grimwood K, et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia’s National Childhood vaccine schedule. Pediatr Infect Dis J. 2011;30(1 Suppl):S25–S29. doi: 10.1097/INF.0b013e3181fefdee.

31. Pendleton A, Galic M, Clarke C, et al. Impact of rotavirus vaccination in Australian children below 5 years of age: a database study. Hum Vaccine Immunother. 2013;9(8):1617–1625. doi: 10.4161/hv.24831.

32. Standaert B, Gomez JA, Raes M, et al. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One. 2013;8(1):e53864. doi: 10.1371/journal.pone.0053864.

33. Vesikari T, Uhari M, Renko M, et al. Impact and effectiveness of RotaTeq® vaccine based on 3 years of surveillance following introduction of a rotavirus immunization program in Finland. Pediatr Infect Dis J. 2013;32(12):1365–1373. doi: 10.1097/Inf.0000000000000086.

34. Yen C, Tate JE, Wenk JD, et al. Diarrhea-associated hospitalizations among US children over 2 rotavirus seasons after vaccine introduction. Pediatrics. 2011;127(1):E9–E15. doi: 10.1542/peds.2010-1393.

35. Payne DC, Staat MA, Edwards KM, et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US Counties, 2006-2009. Clin Infect Dis. 2011;53(3):245–253. doi: 10.1093/cid/cir307.

36. Leshem E, Moritz RE, Curns AT, et al. Rotavirus vaccines and health care utilization for diarrhea in the United States (2007–2011). Pediatrics. 2014;134(1):15–23. doi: 10.1542/peds.2013-3849.

37. Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics. 2011;128(2):e267–275. doi: 10.1542/peds.2010-3722.

38. Wang FT, Mast TC, Glass RJ, et al. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics. 2010;125(2):e208–213. doi: 10.1542/peds.2009-1246.

39. Cortese MM, Parashar UD; Centers for Disease Control and Prevention (CDC). Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2009; 58(RR-2):1–25.

40. Tate JE, Parashar UD. Rotavirus vaccines in routine use. Clin Infect Dis. 2014;59(9):1291–1301. doi: 10.1093/cid/ciu564.

41. Hartwig S, Uhari M, Renko M, et al. Hospital bed occupancy for rotavirus and all cause acute gastroenteritis in two Finnish hospitals before and after the implementation of the national rotavirus vaccination program with RotaTeq. BMC Health Serv Res. 2014;14:632. doi: 10.1186/s12913-014-0632-z.

42. Hemming-Harlo M, Vesikari T, Uhari M, et al. Sustained high effectiveness of RotaTeq on hospitalizations attributable to rotavirus-associated gastroenteritis during 4 Years in Finland. J Pediatric Infect Dis Soc. 2016:piw061. doi: 10.1093/jpids/piw061.

43. www.gov.uk [Internet]. Public Health England. Rotavirus data 2006 to 2015 November 2016. National laboratory data for residents of England and Wales [cited 2017 Jul 1]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/598374/Rotavirus_2016_Data.pdf.

44. Santos VS, Marques DP, Martins-Filho PR, et al. Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis. Infect Dis Poverty. 2016;5(1):83. doi: 10.1186/s40249-016-0173-2.

45. do Carmo GM, Yen C, Cortes J, et al. Decline in diarrhea mortality and admissions after routine childhood rotavirus immunization in Brazil: a time-series analysis. PLoS Med. 2011;8(4):e1001024. doi: 10.1371/journal.pmed.1001024.

46. De Oliveira LH, Giglio N, Ciapponi A, et al. Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. Vaccine. 2013;31 Suppl 3:C99–108. doi: 10.1016/j.vaccine.2013.05.065.

47. Yen C, Armero Guardado JA, Alberto P, et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J. 2011;30(1 Suppl):S6–S10. doi: 10.1097/INF.0b013e3181fefa05.

48. Bayard V, DeAntonio R, Contreras R, et al. Impact of rotavirus vaccination on childhood gastroenteritis-related mortality and hospital discharges in Panama. Int J Infect Dis. 2012;16(2):e94–98. doi: 10.1016/j.ijid.2011.09.003.

49. Becker-Dreps S, Melendez M, Liu L, et al. Community diarrhea incidence before and after rotavirus vaccine introduction in Nicaragua. Am J Trop Med Hyg. 2013;89(2):246–250. doi: 10.4269/ajtmh.13-0026.

50. Inchauste L, Patzi M, Halvorsen K, et al. Impact of rotavirus vaccination on child mortality, morbidity, and rotavirus-related hospitalizations in Bolivia. Int J Infect Dis. 2017;61:79–88. doi: 10.1016/j.ijid.2017.06.006.

51. Quintanar-Solares M, Yen C, Richardson V, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children < 5 years of age in Mexico. Pediatr Infect Dis J. 2011;30(1 Suppl):S11–S15. doi: 10.1097/INF.0b013e3181fefb32.

52. Gastanaduy PA, Sanchez-Uribe E, Esparza-Aguilar M, et al. Effect of rotavirus vaccine on diarrhea mortality in different socioeconomic regions of Mexico. Pediatrics. 2013;131(4):E1115–E1120. doi: 10.1542/peds.2012-2797.

53. Richardson V, Hernandez-Pichardo J, Quintanar-Solares M, et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med. 2010;362(4):299–305. doi: 10.1056/NEJMoa0905211.

54. Lanzieri TM, Linhares AC, Costa I, et al. Impact of rotavirus vaccination on childhood deaths from diarrhea in Brazil. Int J Infect Dis. 2011;15(3):e206–210. doi: 10.1016/j.ijid.2010.11.007.

55. Groome MJ, Page N, Cortese MM, et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis. 2014;14(11):1096–1104. doi: 10.1016/ S1473-3099(14)70940-5.

56. Madhi SA, Cunliffe NA, Steele D, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010;362(4):289–298. doi: 10.1056/NEJMoa0904797.

57. Armah GE, Sow SO, Breiman RF, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–614. doi: 10.1016/S0140-6736(10)60889-6.

58. Рычкова О.А., Казакевич Г.В., Дубинина О.А., и др. Профилактика ротавирусной инфекции: путь расширения региональной программы вакцинации Тюменской области // Фарматека. — 2016. — №11 — С. 106–111. [Rychkova OA, Kazakevich GV, Dubinina OA, et al. Prevention of rotavirus infection: the way of expansion of the regional vaccination program in Tyumen Region. Farmateka. 2016;(11):106–111. (In Russ).]

59. Южакова А.Г., Мартынова Г.П. Вакцинопрофилактика ротавирусной инфекции: социальная значимость и эффективность // Журнал инфектологии. — 2017. — Т.9. — №2 — С. 65–71. [Yuzhakova AG, Martynova GP. Vaccine prevention of rotavirus infection: social significance and effectiveness. Journal Infectology. 2017;9(2):65–71. (In Russ).] doi: 10.22625/2072-6732-2017-9-2-65-71.

60. Lopman BA, Payne DC, Tate JE, et al. Post-licensure experience with rotavirus vaccination in high and middle income countries; 2006 to 2011. Curr Opin Virol. 2012;2(4):434–442. doi: 10.1016/j.coviro.2012.05.002.

61. Lambert SB, Faux CE, Hall L, et al. Early evidence for direct and indirect effects of the infant rotavirus vaccine program in Queensland. Med J Aust. 2009;191(3):157–160.

62. Patel MM, Steele D, Gentsch JR, et al. Real-world impact of rotavirus vaccination. Pediatr Infect Dis J. 2011;30(1 Suppl):S1–5. doi: 10.1097/INF.0b013e3181fefa1f.

63. Field EJ, Vally H, GrimwoodK, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics. 2010;126(3):e506–512. doi: 10.1542/peds.2010-0443.

64. Raes M, Strens D, Vergison A, et al. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J. 2011;30(7):e120–125. doi: 10.1097/INF.0b013e318214b811.

65. Safadi MA, Berezin EN, Munford V, et al. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. Pediatr Infect Dis J. 2010;29(11):1019–1022. doi: 10.1097/INF.0b013e3181e7886a.

66. Lopman BA, Curns AT, Yen C, Parashar UD. Infant rotavirus vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis. 2011;204(7):980–986. doi: 10.1093/infdis/jir492.

67. Anderson E. Rotavirus decreased in adults after widespread vaccination among children [Internet]. IDSA 49th Annual Meeting [updated 2011 October 21; cited 2017 Aug 1]. Available from: https://www.healio.com/pediatrics/vaccine-preventable-diseases/news/online/%7B6ae3569a-8446-4f3a-bb14-2f45a70a59aa%7D/rotavirus-decreased-in-adults-after-widespread-vaccination-among-children.

68. Cortese MM, Dahl RM, Curns AT, Parashar UD. Protection against gastroenteritis in US households with children who received rotavirus vaccine. J Infect Dis. 2015;211(4):558–562. doi: 10.1093/infdis/jiu503.

69. Anderson EJ, Shippee DB, Weinrobe MH, et al. Indirect protection of adults from rotavirus by pediatric rotavirus vaccination. Clin Infect Dis. 2013;56(6):755–760. doi: 10.1093/cid/cis1010.

70. Pitzer VE, Atkins KE, de Blasio BF, et al. Direct and indirect effects of rotavirus vaccination: comparing predictions from transmission dynamic models. PLoS One. 2012;7(8):e42320. doi: 10.1371/journal.pone.0042320.

71. Standaert B, Strens D, Alwan A, Raes M. Mediumto long-term impact of rotavirus vaccination on hospital care in Belgium: a 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). Infect Dis Ther. 2016;5(1):31–44. doi: 10.1007/s40121-015-0099-1.

72. Atherly D, Dreibelbis R, Parashar UD, et al. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis. 2009;200 Suppl 1:S28–S38. doi: 10.1086/605033.

73. Uprety P, Lindsey JC, Levin MJ, et al. Inflammation and immune activation in antiretroviral-treated human immunodeficiency virus type 1-infected African infants and rotavirus vaccine responses. J Infect Dis. 2017;215(6):928–932. doi: 10.1093/infdis/jix060.

74. Wendy B. Vaccination with 3-dose paediatric rotavirus vaccine (RotaTeq): impact on the timeliness of uptake of the primary course of DTPa vaccine. Vaccine. 2012;30(35):5293–5297. doi: 10.1016/j.vaccine.2012.04.071.

75. Rivero-Calle I, Gomez-Rial J, Martinon-Torres F. Systemic features of rotavirus infection. J Infect. 2016;72 Suppl:S98–S105. doi: 10.1016/j.jinf.2016.04.029.

76. Blutt SE, Matson DO, Crawford SE, et al. Rotavirus antigenemia in children is associated with viremia. PLoS Med. 2007;4(4):660–668. doi: 10.1371/journal.pmed.0040102.

77. Dalgıç N, Haşim Ö, Pullu M, et al. Is rotavirus diarrhea a systemic viral infection? Çocuk Enf Derg. 2010;4(2):48–55.

78. Payne DC, Baggs J, Zerr DM, et al. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014;58(2):173-177. doi: 10.1093/cid/cit671.

79. Рудакова А.В., Харит С.М., Усков А.Н., Лобзин Ю.В. Оценка предотвращенных затрат на терапию ротавирусной инфекции при вакцинации 5-валентной вакциной в Российской Федерации // Журнал инфектологии. — 2014. — Т.6. — №2 — С. 71–75. [Rudakova AV, Kharit SM, Uskov AN, Lobzin Yu V. Otsenka predotvrashchennykh zatrat na terapiyu rotavirusnoi infektsii pri vaktsinatsii 5-valentnoi vaktsinoi v Rossiiskoi Federatsii. Zhurnal infektologii. 2014:6(2);71–75 (In Russ).]